Verona Pharma plc (VRNA) has 20 既知のインサイダーおよび機関投資家保有者の記録. 最大保有者は Blavatnik Len 55,911,648 株保有. その他の主要保有者には Access Industries Holdings LLC および ZACCARDELLI DAVID.
過去12ヶ月間にインサイダーは 40 件の取引を実施 VRNA 株式 — 16 件の買い (評価額 $431.64K) および 15 件の売り (評価額 $26.87M). インサイダーの買いが売りを上回っており、会社の見通しに対する自信の表れかもしれません.
VRNA インサイダー保有状況
最大保有者
Blavatnik Len
55,911,648 株
インサイダー上位保有者
| # |
氏名 |
役職 |
保有株数 |
最終申告日 |
相対規模 |
| 1 |
Blavatnik Len |
Director |
55,911,648 |
2022-08-17 |
|
| 2 |
Access Industries Holdings Llc |
10 Percent Owner |
51,111,648 |
2022-08-17 |
|
| 3 |
Zaccardelli David |
President and CEO |
13,190,168 |
2025-06-13 |
|
| 4 |
Hahn Mark W |
Chief Financial Officer |
12,278,992 |
2025-06-13 |
|
| 5 |
Makower Joshua |
10 Percent Owner |
9,757,393 |
2021-01-04 |
|
| 6 |
Sonsini Peter W. |
10 Percent Owner |
9,757,393 |
2021-01-04 |
|
| 7 |
Makhzoumi Mohamad |
10 Percent Owner |
9,757,393 |
2021-01-04 |
|
| 8 |
Baskett Forest |
10 Percent Owner |
9,757,393 |
2021-01-04 |
|
| 9 |
Florence Anthony A. Jr. |
10 Percent Owner |
9,757,393 |
2021-01-04 |
|
| 10 |
Sandell Scott D |
10 Percent Owner |
9,757,393 |
2021-01-04 |
|
| 11 |
Orbimed Advisors Llc |
Director |
4,180,691 |
2023-05-15 |
|
| 12 |
Gupta Rishi |
Director |
4,180,691 |
2023-05-15 |
|
| 13 |
Rickard Kathleen A. |
Chief Medical Officer |
2,546,472 |
2025-05-08 |
|
| 14 |
Poll Claire |
General Counsel |
1,176,920 |
2024-02-05 |
|
| 15 |
Fisher Andrew |
General Counsel |
439,999 |
2025-06-18 |
|
| 16 |
Ebsworth David R |
Director |
96,000 |
2025-04-29 |
|
| 17 |
Ullman Anders |
Director |
96,000 |
2025-04-29 |
|
| 18 |
Brady James Aloysius |
Director |
96,000 |
2025-04-29 |
|
| 19 |
Austwick Michael |
Director |
96,000 |
2025-04-29 |
|
| 20 |
Deschamps Lisa |
Director |
96,000 |
2025-04-29 |
|
最近の取引 (過去12ヶ月)
| 日付 |
氏名 |
役職 |
種類 |
株数 |
株価 |
価値 |
| 2025-06-16 |
Fisher Andrew |
General Counsel |
情報に基づく売り |
80,000 |
$11.53 |
$922K |
| 2025-05-15 |
Fisher Andrew |
General Counsel |
オプション行使 |
80,000 |
$2.01 |
$160.9K |
| 2025-06-11 |
Zaccardelli David |
President and CEO |
情報に基づく売り |
400,000 |
$11.40 |
$4.56M |
| 2025-06-11 |
Hahn Mark W |
Chief Financial Officer |
情報に基づく売り |
400,000 |
$11.40 |
$4.56M |
| 2025-05-29 |
Zaccardelli David |
President and CEO |
情報に基づく売り |
208,696 |
$9.33 |
$1.95M |
| 2025-05-28 |
Zaccardelli David |
President and CEO |
情報に基づく売り |
157,704 |
$9.30 |
$1.47M |
| 2025-05-27 |
Zaccardelli David |
President and CEO |
情報に基づく売り |
33,600 |
$9.53 |
$320.18K |
| 2025-05-29 |
Hahn Mark W |
Chief Financial Officer |
情報に基づく売り |
204,864 |
$9.33 |
$1.91M |
| 2025-05-28 |
Hahn Mark W |
Chief Financial Officer |
情報に基づく売り |
162,704 |
$9.30 |
$1.51M |
| 2025-05-27 |
Hahn Mark W |
Chief Financial Officer |
情報に基づく売り |
32,432 |
$9.53 |
$308.98K |
| 2025-05-20 |
Sinha Vikas |
Director |
オプション行使（売却） |
160,000 |
$0.50 |
$80.61K |
| 2025-04-29 |
Sinha Vikas |
Director |
オプション行使（売却） |
120,384 |
$1.70 |
$204.65K |
| 2025-05-15 |
Fisher Andrew |
General Counsel |
情報に基づく売り |
80,000 |
$8.57 |
$685.6K |
| 2025-05-14 |
Ackermann Christina |
Director |
情報に基づく売り |
40,000 |
$8.44 |
$337.6K |
| 2025-05-06 |
Rickard Kathleen A. |
Chief Medical Officer |
情報に基づく売り |
114,984 |
$8.82 |
$1.01M |
| 2025-05-01 |
Rickard Kathleen A. |
Chief Medical Officer |
オプション行使（売却） |
50,000 |
- |
- |
| 2025-05-02 |
Zaccardelli David |
President and CEO |
情報に基づく売り |
400,000 |
$9.09 |
$3.64M |
| 2025-05-01 |
Zaccardelli David |
President and CEO |
オプション行使（売却） |
200,000 |
- |
- |
| 2025-05-02 |
Hahn Mark W |
Chief Financial Officer |
情報に基づく売り |
400,000 |
$9.09 |
$3.64M |
| 2025-05-01 |
Hahn Mark W |
Chief Financial Officer |
オプション行使（売却） |
200,000 |
- |
- |
| 2025-05-01 |
Ebsworth David R |
Director |
オプション行使 |
140,000 |
$1.93 |
$270.73K |
| 2025-04-29 |
Fisher Andrew |
General Counsel |
オプション行使（売却） |
86,064 |
- |
- |
| 2025-03-19 |
Fisher Andrew |
General Counsel |
贈与（受領） |
1 |
- |
- |
| 2025-04-29 |
Rickard Kathleen A. |
Chief Medical Officer |
オプション行使（売却） |
86,064 |
- |
- |
| 2024-08-07 |
Rickard Kathleen A. |
Chief Medical Officer |
RSU 付与（制限付株式） |
300,000 |
- |
- |
